These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 2895853

  • 21. Letter: Pseudomonas septicaemia following superficial colonization.
    Spiers AS.
    Br Med J; 1974 Dec 28; 4(5947):770. PubMed ID: 4216391
    [No Abstract] [Full Text] [Related]

  • 22. Carbenicillin plus cephalothin or cefazolin as therapy for infections in neutropenic patients.
    Bodey GP, Valdivieso M, Feld R, Rodriguez V, McCredie K.
    Am J Med Sci; 1977 Dec 28; 273(3):309-18. PubMed ID: 326048
    [No Abstract] [Full Text] [Related]

  • 23. To the editor: Is it safe to administer a continuous infusion of ceftazidime (Fortum) prepared for 24 hours in cystic fibrosis (CF) patients?
    Plasse JC, Chabloz C, Terrier A, Bellon G.
    Pediatr Pulmonol; 2002 Mar 28; 33(3):232-3. PubMed ID: 11836805
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Primary cutaneous bacillus cereus infection in neutropenic children.
    Henrickson KJ, Shenep JL, Flynn PM, Pui CH.
    Lancet; 1989 Mar 18; 1(8638):601-3. PubMed ID: 2564122
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
    Alou L, Aguilar L, Sevillano D, Giménez MJ, Echeverría O, Gómez-Lus ML, Prieto J.
    J Antimicrob Chemother; 2005 Feb 18; 55(2):209-13. PubMed ID: 15650000
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers.
    Lemmen SW, Engels I, Daschner FD.
    J Antimicrob Chemother; 1997 Jun 18; 39(6):841-2. PubMed ID: 9222063
    [No Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of azlocillin and ticarcillin in febrile neutropenic children with cancer: a comparative study.
    Kosmidis H, Varvoutsi M, Kafetzis D, Koupari G, Bouhoutsou D, Papadatos C.
    Chemioterapia; 1987 Jun 18; 6(2 Suppl):396-8. PubMed ID: 3334581
    [No Abstract] [Full Text] [Related]

  • 31. [Ceftazidime: advantages of continuous infusions in a patient with aplasia].
    Legrand O, Marie JP, Bardin C, Bezie Y, Hermelin C, Herrmann JL, Chast F, Zittoun R.
    Presse Med; 1987 Jun 18; 22(16):786. PubMed ID: 8316540
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.
    Opal SM, Cross AS, Kelly NM, Sadoff JC, Bodmer MW, Palardy JE, Victor GH.
    J Infect Dis; 1990 Jun 18; 161(6):1148-52. PubMed ID: 2140582
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
    Babalola CP, Nightingale CH, Nicolau DP.
    Int J Antimicrob Agents; 2004 Sep 18; 24(3):219-25. PubMed ID: 15325424
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.